THE DEFINITIVE GUIDE TO HEMGENIX

Quantity of suitable people: CDEC discussed the uncertainty in the number of patients with reasonably intense to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific professionals consulted by CADTH indicated that some sufferers who are classified as having moderate or average condition might have a serious bleeding